NCT03165201 (RADIcAL2) is a clinical trial of LiverMultiScan in Liver Transplantation, sponsored by Perspectum.

Who is sponsoring NCT03165201?

NCT03165201 is sponsored by Perspectum.

What drugs are being tested in NCT03165201?

Interventions in NCT03165201: LiverMultiScan.

What condition does NCT03165201 study?

NCT03165201 studies Liver Transplantation.

Is NCT03165201 still recruiting?

NCT03165201 is currently completed. Last updated 29 April 2021.

Last reviewed 2021-04-29 · How we verify

NCT03165201: RADIcAL2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-Invasive Rapid Assessment of Patients With Liver Transplants Using Magnetic Resonance Imaging With LiverMultiScan

Completed Last updated 29 April 2021

What this trial tests

trial testing LiverMultiScan in Liver Transplantation in 131 participants. Completed in 1 October 2020.

Timeline

18 September 2017

Primary endpoint
1 August 2020

1 October 2020

Quick facts

Lead sponsor	Perspectum
Status	Completed
Study type	OBSERVATIONAL
Enrollment	131
Start date	18 September 2017
Primary completion	1 August 2020
Estimated completion	1 October 2020
Sites	3 locations across Portugal, United Kingdom, Netherlands

Drugs / interventions tested

LiverMultiScan

Conditions studied

Liver Transplantation — all drugs for Liver Transplantation →

Sponsor

Perspectum

Who can join

Adults 6 to 75, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a prospective, multi-centre, biomarker trial comparing the accuracy of a new test (LiverMultiScan) against an existing test (liver biopsy) in the assessment of liver transplant recipients, designed in accordance with the STARD criteria. Study participants are 200 patients with liver transplant, due to undergo liver biopsy as part of serial evaluation of their liver health and to rule out rejection. The whole study will take 3 years with 2 years of recruitment The main aim is to investigate whether the introduction of LiverMultiScan as a standardised diagnostic test for liver disease can match the diagnostic yield of existing biopsies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study.
McDonald N, Eddowes PJ, Hodson J, Semple SIK, et al · · 2018 · cited 60× · PMID 29907829 · DOI 10.1038/s41598-018-27560-5
MRI-serum-based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: A multisite European study.
Schaapman J, Shumbayawonda E, Castelo-Branco M, Caseiro Alves F, et al · · 2025 · cited 9× · PMID 39171987 · DOI 10.1097/lvt.0000000000000450
The Role of the Multiparametric MRI LiverMultiScan<sup>TM</sup> in the Quantitative Assessment of the Liver and Its Predicted Clinical Applications in Patients Undergoing Major Hepatic Resection for Colorectal Liver Metastasis.
Chouari T, Merali N, La Costa F, Santol J, et al · · 2023 · cited 5× · PMID 37835557 · DOI 10.3390/cancers15194863

Verify or expand the search:

Other trials of LiverMultiScan

Trials testing the same drug.

NCT03289897 — Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan · NA · completed
NCT03743272 — Repeatability and Reproducibility of Multiparametric MRI · completed

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

NCT07157631 — Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial · NA · recruiting
NCT07123740 — Comparison of the Postoperative Analgesic Effects of ITM and Bi-level ESPB in Liver Transplantation Donors · NA · recruiting
NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting
NCT06868589 — Reducing Pain With Methadone and Ketamine in Liver Transplant · Phase 4 · active not recruiting
NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting

Other Perspectum trials

Trials by the same sponsor.

NCT07098650 — Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System · recruiting
NCT04974710 — Developing an US-MRI Biomarker Fusion Model for Endometriosis · completed
NCT05326191 — First-trimester Placental Ultrasound Study · completed
NCT05000242 — West Hertfordshire Inflammatory Bowel Disease Technology Study · active not recruiting
NCT05110248 — Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03165201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Perspectum
Last refreshed: 29 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03165201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing